Acute Lymphoblastic Leukemia News and Research

RSS

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.

Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients

Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.

7 Dec 2010

New drug appears to help patients with chronic myeloid leukemia

A new drug appears to help chronic myeloid leukemia patients who are out of treatment options after first- and second-line drugs have failed them or because their cancer cells have a mutation that makes them resistant from the start, researchers reported at the 52nd Annual Meeting of the American Society of Hematology.

7 Dec 2010

$Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH$

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from a fully enrolled and ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with resistant and refractory chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.

6 Dec 2010

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology provides greater understanding of the optimal use of several BCR-ABL inhibitors for the treatment of acute lymphoblastic leukemia and chronic myeloid leukemia, and how a new gene target functions for several myeloid malignancies.

6 Dec 2010

Mitoxantrone increases survival for children with relapsed ALL, trial results show

A new treatment increases survival to almost 70 per cent for children whose acute lymphoblastic leukaemia returns, according to the results of a trial published online in the Lancet today (Saturday).

4 Dec 2010

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

Xencor, Inc. and MorphoSys AG announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208), and the first patient has been dosed. XmAb5574 (MOR208) is a potent monoclonal anti-CD19 antibody to which MorphoSys recently gained worldwide access via an exclusive license and collaboration agreement with Xencor.

2 Dec 2010

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

ARIAD Pharmaceuticals, Inc. today announced that updated clinical data from a fully enrolled Phase 1 trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be presented at the 52nd Annual Meeting of the American Society of Hematology being held in Orlando, Florida, December 4-7, 2010.

30 Nov 2010

Overexpression of microRNA 125b can cause leukemia: Research

Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression. Their results are published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS).

30 Nov 2010

Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that data regarding Marqibo for treatment of adults with relapsed/refractory acute lymphoblastic leukemia (ALL) will be the subject of two presentations at the 2010 Annual Meeting and Exposition of the American Society of Hematology (ASH) being held in Orlando, Florida from December 4-7, 2010.

30 Nov 2010

JAK3 pathway highlighted as leukemia target

An intriguing study published in Expert Review of Anticancer Therapy has revealed that the signaling protein JAK3 represents a viable target in the treatment of a broad range of B-lineage cancers, including acute lymphoblastic leukemia (ALL).

28 Nov 2010

Dollar General joins St. Jude Children's Hospital for Thanks and Giving campaign

This holiday season, Dollar General again joins St. Jude Children's Research Hospital for the Thanks and Giving campaign by asking customers to "give thanks for the healthy kids in your life, and give to those who are not."

20 Nov 2010

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States.

17 Nov 2010

Hana Biosciences announces financial results of third quarter 2010

Hana Biosciences, Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the three and nine months ended September 30, 2010, and provided a corporate update.

12 Nov 2010

ARIAD reports $20.4 million net loss for third quarter 2010

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2010 and provided an update on corporate developments.

9 Nov 2010

EUSA completes BLA filing for ERWINASE in treatment of acute lymphoblastic leukemia

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ERWINASE(R) (L-asparaginase derived from Erwinia chrysanthemi) for use in the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived asparaginase.

9 Nov 2010

EUSA Pharma announces 10-year outcome data of PROSTASCINT in prostate cancer radiotherapy

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced today the publication of 10-year outcome data showing that PROSTASCINT(R) (capromab pendetide) fusion imaging is an effective tool for targeting and guiding the dosing of prostate cancer radiotherapy.

4 Nov 2010

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has received a grant of $244,479 from the United States Government to help fund the Company's Phase I clinical trial of its lead cancer drug candidate Liposomal Grb-2. The amount of funds awarded was the maximum allocation allowed under the program.

4 Nov 2010

EUSA announces publication of PROSTASCINT imaging for prostate cancer in official journal of American Society

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced today the publication of 10-year outcome data showing that PROSTASCINT (capromab pendetide) fusion imaging is an effective tool for targeting and guiding the dosing of prostate cancer radiotherapy.

3 Nov 2010

The Melting Pot joins St. Jude in seventh annual Thanks and Giving campaign

The Melting Pot Restaurants join St. Jude Children's Research Hospital in the seventh annual Thanks and Giving campaign from Nov. 1 - Dec. 4, to give thanks for the healthy kids in your life, and give to those who are not by donating to cancer research.

30 Oct 2010

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

After receiving a priority review, Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved SPRYCEL (dasatinib) 100 mg once daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.

29 Oct 2010

Acute Lymphoblastic Leukemia News and Research

Further Reading

Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients

New drug appears to help patients with chronic myeloid leukemia

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Mitoxantrone increases survival for children with relapsed ALL, trial results show

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

Overexpression of microRNA 125b can cause leukemia: Research

Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

JAK3 pathway highlighted as leukemia target

Dollar General joins St. Jude Children's Hospital for Thanks and Giving campaign

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

Hana Biosciences announces financial results of third quarter 2010

ARIAD reports $20.4 million net loss for third quarter 2010

EUSA completes BLA filing for ERWINASE in treatment of acute lymphoblastic leukemia

EUSA Pharma announces 10-year outcome data of PROSTASCINT in prostate cancer radiotherapy

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

EUSA announces publication of PROSTASCINT imaging for prostate cancer in official journal of American Society

The Melting Pot joins St. Jude in seventh annual Thanks and Giving campaign

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News